Add this topic to your myFT Digest for news straight to your inbox
Evobrutinib failed to reduce relapse rates compared with teriflunomide, produced by rival Sanofi
Pharma group behind blockbuster drug wants to supersize its market impact
Science secretary Michelle Donelan signs post-Brexit deal to rejoin €96bn research scheme
Deal with Absci is the latest between big pharma and tech companies to build new disease treatments
Decision is setback for US drugmaker looking to increase sales after pandemic
Innovative models can drive funding for research on neglected, less survivable diseases
Danish pharma group in talks with healthcare providers about innovative models to boost Wegovy take-up
Bill Anderson says group is generating a series of promising new drugs after R&D strategy change
Government to boost spending on computing power by £500mn to develop artificial intelligence
A new crop of weight-loss drugs is disrupting markets as well as transforming waistlines
T-Therapeutics hopes to use genetically engineered rodents and machine learning to discover drugs
Wegovy found to have ‘quite profound’ effect on reducing risk of heart attacks, says pharma group
The UK should take inspiration from the inventors and implementers of its industrial revolution
Anglo-Swedish drugmaker’s oncology and rare disease medication sales offset waning demand for Covid jabs
Drugmakers claim that Brussels’ market exclusivity overhaul will reduce R&D investment
Emerging research is challenging a widely held belief that new cases of the condition will rise exponentially as people live longer
UK Biobank’s records of 500,000 people promise breakthroughs in diseases and ageing
Pioneering medicines developed by Eisai and Eli Lilly shown to be more effective when taken earlier
Biotech acquisitions this year intended to cement position as market leaders in weight-loss field
Bolt-on acquisitions, however interesting, will not get Swiss pharmaceuticals group Roche out of its funk
Drugmaker upbeat on full data after initial findings disappointed investors
Swiss pharma group acquires rights to develop and manufacture bowel disease treatment
Pioneering British sector drives development of more fuel-efficient aircraft, but admits it is a ‘huge opportunity’ and a ‘big risk’
No, but it’s mildly interesting to ask
The government has work to do to make the UK more welcoming for drugmakers
International Edition